156 related articles for article (PubMed ID: 9042316)
21. Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Peron K; Jones TN; Gauthier SA; Nguyen TN; Zang XP; Barriere M; Prévéraud D; Soliman CE; Harrison RG; Pento JT
Cancer Chemother Pharmacol; 2003 Oct; 52(4):270-6. PubMed ID: 12827296
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes L-methioninase.
El-Sayed AS; Shouman SA; Nassrat HM
Enzyme Microb Technol; 2012 Sep; 51(4):200-10. PubMed ID: 22883554
[TBL] [Abstract][Full Text] [Related]
25. The preparation of endotoxin-free L-methionine-alpha-deamino-gamma-mercaptomethane-lyase (L-methioninase) from Pseudomonas putida.
Lishko VK; Lishko OV; Hoffman RM
Protein Expr Purif; 1993 Dec; 4(6):529-33. PubMed ID: 8286949
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
27. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
28. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
Rupp U; Schoendorf-Holland E; Eichbaum M; Schuetz F; Lauschner I; Schmidt P; Staab A; Hanft G; Huober J; Sinn HP; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Apr; 18(4):477-85. PubMed ID: 17351401
[TBL] [Abstract][Full Text] [Related]
29. Development of Recombinant Methioninase for Cancer Treatment.
Hoffman RM; Tan Y; Li S; Han Q; Yagi S; Takakura T; Takimoto A; Inagaki K; Kudou D
Methods Mol Biol; 2019; 1866():107-131. PubMed ID: 30725412
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates.
Yang Z; Wang J; Yoshioka T; Li B; Lu Q; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
Clin Cancer Res; 2004 Mar; 10(6):2131-8. PubMed ID: 15041734
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
O'Byrne KJ; Dobbs N; Propper DJ; Braybrooke JP; Koukourakis MI; Mitchell K; Woodhull J; Talbot DC; Schally AV; Harris AL
Br J Cancer; 1999 Mar; 79(9-10):1413-8. PubMed ID: 10188884
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
[TBL] [Abstract][Full Text] [Related]
33. Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey.
Hoffman RM
Expert Opin Biol Ther; 2015 Jan; 15(1):21-31. PubMed ID: 25439528
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
[TBL] [Abstract][Full Text] [Related]
36. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
[TBL] [Abstract][Full Text] [Related]
37. Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
Han Q; Tan Y; Hoffman RM
Anticancer Res; 2020 May; 40(5):2813-2819. PubMed ID: 32366428
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee.
Carmichael J; Jones A; Hutchinson T
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-44-S17-47. PubMed ID: 9374092
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel plus doxorubicin in breast cancer: an Italian experience.
Frassineti GL; Zoli W; Silvestro L; Serra P; Milandri C; Tienghi A; Gianni L; Gentile A; Salzano E; Amadori D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-19-S17-25. PubMed ID: 9374087
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
